BR112022015827A2 - Inibidores de tirosina quinase de fgfr para o tratamento de câncer de bexiga invasivo não muscular de alto risco - Google Patents

Inibidores de tirosina quinase de fgfr para o tratamento de câncer de bexiga invasivo não muscular de alto risco

Info

Publication number
BR112022015827A2
BR112022015827A2 BR112022015827A BR112022015827A BR112022015827A2 BR 112022015827 A2 BR112022015827 A2 BR 112022015827A2 BR 112022015827 A BR112022015827 A BR 112022015827A BR 112022015827 A BR112022015827 A BR 112022015827A BR 112022015827 A2 BR112022015827 A2 BR 112022015827A2
Authority
BR
Brazil
Prior art keywords
bladder cancer
treatment
tyrosine kinase
kinase inhibitors
high risk
Prior art date
Application number
BR112022015827A
Other languages
English (en)
Inventor
Monga Manish
Ali Baig Mahadi
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BR112022015827A2 publication Critical patent/BR112022015827A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

INIBIDORES DE TIROSINA QUINASE DE FGFR PARA O TRATAMENTO DE CÂNCER DE BEXIGA INVASIVO NÃOMUSCULAR DE ALTO RISCO. A presente invenção se refere a métodos de tratamento de câncer de bexiga invasivo não muscular de alto risco (HR-NMIBC) que compreendem administrar um inibidor de receptor de fator de crescimento de fibroblasto (FGFR). Também são descritos métodos de tratamento de câncer de bexiga invasivo não muscular de risco intermediário (IR-NMIBC) que compreendem administrar um inibidor de FGFR.
BR112022015827A 2020-02-12 2021-02-11 Inibidores de tirosina quinase de fgfr para o tratamento de câncer de bexiga invasivo não muscular de alto risco BR112022015827A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202062975547P 2020-02-12 2020-02-12
US202063018914P 2020-05-01 2020-05-01
US202063118475P 2020-11-25 2020-11-25
PCT/EP2021/053385 WO2021160764A1 (en) 2020-02-12 2021-02-11 Fgfr tyrosine kinase inhibitors for the treatment of high-risk non-muscle invasive bladder cancer

Publications (1)

Publication Number Publication Date
BR112022015827A2 true BR112022015827A2 (pt) 2022-10-04

Family

ID=74666675

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022015827A BR112022015827A2 (pt) 2020-02-12 2021-02-11 Inibidores de tirosina quinase de fgfr para o tratamento de câncer de bexiga invasivo não muscular de alto risco

Country Status (13)

Country Link
US (1) US20230110113A1 (pt)
EP (1) EP4103185A1 (pt)
JP (1) JP2023513704A (pt)
KR (1) KR20220140781A (pt)
CN (1) CN115103678A (pt)
AU (1) AU2021220285A1 (pt)
BR (1) BR112022015827A2 (pt)
CA (1) CA3162962A1 (pt)
IL (1) IL295514A (pt)
JO (1) JOP20220182A1 (pt)
MX (1) MX2022009905A (pt)
TW (1) TW202143970A (pt)
WO (1) WO2021160764A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL312063A (en) * 2021-10-12 2024-06-01 Taris Biomedical Llc Ardafitinib formulations and systems for intravesical administration
WO2023159216A1 (en) * 2022-02-18 2023-08-24 Taris Biomedical Llc Erdafitinib formulations and osmotic systems for intravesical administration
WO2024170495A1 (en) * 2023-02-13 2024-08-22 Janssen Pharmaceutica Nv Fgfr tyrosine kinase inhibitors for the treatment of high-risk non-muscle invasive bladder cancer
WO2024173377A1 (en) * 2023-02-13 2024-08-22 Taris Biomedical Llc Erdafitinib for intravesical administration for use in the treatment of bladder cancer
WO2024173716A1 (en) * 2023-02-17 2024-08-22 Taris Biomedical Llc Erdafitinib for intravesical administration for use in the treatment of bladder cancer

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
CA2262403C (en) 1995-07-31 2011-09-20 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate disease
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
CA2609353C (en) 2005-05-23 2015-04-28 Novartis Ag Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactic acid salts
US8163923B2 (en) 2007-03-14 2012-04-24 Advenchen Laboratories, Llc Spiro substituted compounds as angiogenesis inhibitors
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
SG11201702381QA (en) 2014-09-26 2017-04-27 Janssen Pharmaceutica Nv Use of fgfr mutant gene panels in identifying cancer patients that will be responsive to treatment with an fgfr inhibitor
JOP20200201A1 (ar) * 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
EA201991818A1 (ru) * 2017-12-20 2020-02-05 Янссен Фармацевтика Нв Лечение рака

Also Published As

Publication number Publication date
EP4103185A1 (en) 2022-12-21
JOP20220182A1 (ar) 2023-01-30
TW202143970A (zh) 2021-12-01
US20230110113A1 (en) 2023-04-13
WO2021160764A1 (en) 2021-08-19
JP2023513704A (ja) 2023-04-03
AU2021220285A1 (en) 2022-10-06
CA3162962A1 (en) 2021-08-19
CN115103678A (zh) 2022-09-23
MX2022009905A (es) 2022-08-25
IL295514A (en) 2022-10-01
KR20220140781A (ko) 2022-10-18

Similar Documents

Publication Publication Date Title
BR112022015827A2 (pt) Inibidores de tirosina quinase de fgfr para o tratamento de câncer de bexiga invasivo não muscular de alto risco
BR112022024729A2 (pt) Inibidores de quinases do receptor do fator de crescimento de fibroblastos
CO2021017981A2 (es) Inhibidores heterobicíclicos de mat2a y métodos de uso para el tratamiento del cáncer
ECSP22083904A (es) Compuestos, composiciones farmacéuticas y métodos para la preparación de compuestos y para su uso
MX2021014455A (es) Inhibidores de proteina cinasas dependientes de adn.
MX2013004086A (es) Metodos para inhibir proliferacion celular en cancers accionados por egfr.
EA202092320A1 (ru) Гетеробициклические ингибиторы mat2a и способы использования для лечения злокачественной опухоли
MX2021003517A (es) Composiciones de inhibidor de tirosina quinasa, metodos de fabricacion y metodos de uso.
CL2021001722A1 (es) Inhibidores aza-heterobicíclicos de mat2a y métodos de uso en el tratamiento de cáncer
UA108863C2 (ru) Бензоксепиновые ингибиторы pi3 и их применение
ECSP109965A (es) Imidazoles fusionados para el tratamiento del cancer
ECSP109957A (es) Derivados de pirimidinil-piridazinona.
EA201270373A1 (ru) Ингибиторы jak2 и их применение для лечения миелопролиферативных заболеваний и злокачественной опухоли
UY31757A1 (es) Combinación del inhibidor hgf y el inhibidor egf para el tratamiento del cáncer
ECSP10010248A (es) Inhibidores de cinesina como productos terapéuticos para el cáncer
ECSP088706A (es) Antagonistas de receptor de factor de crecimiento de tipo insulina (igf-ir) como auxiliares para tratamiento de cáncer de próstata
CO6290671A2 (es) Compuestos que comprenden heterociclos espirociclicos como inhibidores de la tirosina quinasa y procedimiento para su preparacion
BR112021019203A2 (pt) Inibidores de tirosina quinase fgfr para o tratamento de carcinoma urotelial
EA201170660A1 (ru) Избирательная для erbb-3 (her3) комбинированная терапия
MX2021006619A (es) Inhibidores de la tirosina quinasa, composiciones y sus metodos.
CL2023002486A1 (es) Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso
MX2021012705A (es) Compuestos con actividad antitumoral contra las celulas cancerosas que portan mutaciones en el receptor del factor de crecimiento epidermico (egfr) resistentes al inhibidor de la tirosina quinasa.
MX2021009426A (es) Derivados de indazolil-isoxazol para el tratamiento de enfermedades tales como cancer.
CO2022019316A2 (es) Inhibidores alostéricos de egfr y métodos de uso de estos
BR112023012947A2 (pt) Inibidores de lrrk2